ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: A cohort study

BMJ Open

Volumn 3, Issue 11, 2013, Pages

  Lauridsen, Bo K ^a   Iversen, Kasper ^a   Hunter, Ingrid ^a   Bay, Morten ^b   Kirk, Vibeke ^c   Nielsen, Olav W ^d   Nielsen, Henrik ^d   Boesgaard, Søren ^a   Køber, Lars ^a   Goetze, Jens P ^a  

^a Rigshospitalet   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY;

EID: 84889587870     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003288     Document Type: Article

References (35)

1. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
2. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
3. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010;31:3024-31.
4. Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009;53:1783-90.
5. Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008;51:1857-64.
6. Van Hateren KJ, Alkhalaf A, Kleefstra N, et al. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. Clin Chem 2012;58:293-7.
7. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
8. Wallén T, Landahl S, Hedner T, et al. Brain natriuretic peptide in an elderly population. J Intern Med 1997;242:307-11.
9. Christ M, Thuerlimann A, Laule K, et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest 2007;37:834-41.
10. Bay M, Kirk V, Parner J, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-4.
11. Kirk V, Bay M, Parner J, et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004;6:335-41.
12. Wendelboe Nielsen O, Kirk V, Bay M, et al. Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF). Eur J Heart Fail 2004;6:275-9.
13. Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in mammals by processing independent analysis. J Immunol Methods 2011;370:104-10.
14. Hunter I, Alehagen U, Dahlström U, et al. Peptide measurement in plasma suggests covalent modification. Clin Chem 2011;57:1327-30.
15. Goetze JP, Hunter I, Lippert SK, et al. Processing-independent analysis of peptide hormones and prohormones in plasma. Front Biosci 2012;17:1804-15.
16. Karl J, Borgya A, Gallusser A, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-81.
17. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974;19:716-23.
18. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
19. Harrell FE Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
20. Newson RB. Comparing the predictive powers of survival models using Harrell's C or Somers ' D. Stata J 2010;10:339-58.
21. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109-20.
22. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
23. Alehagen U, Dahlström U, Rehfeld JF, et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 2011;305:2088-95.
24. Alehagen U, Dahlström U, Rehfeld JF, et al. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. Clin Chem 2010;56:1718-24.
25. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-16.
26. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 2010;55:2140-7.
27. Linssen GC, Bakker SJ, Voors AA, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 2010;31:120-7.
28. Gruson D, Rousseau MF, Ahn S, et al. Accuracy of N-terminal-pro-atrial natriuretic peptide in patients admitted to emergency department. Scand J Clin Lab Invest 2008; 68:410-14.
29. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-4.
30. McCullough PA, Nowak RM, McCord J. B-Type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-22.
31. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
32. Januzzi JL Jr, Sakhuja R, O'donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006;166:315-20.
33. Rehman SU, Martinez-Rumayor A, Mueller T, et al. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392:41-5.
34. Chong CP, Ryan JE, Van Gaal WJ, et al. Usefulness of N-terminal pro-brain natriuretic peptide to predict postoperative cardiac complications and long-term mortality after emergency lower limb orthopedic surgery. Am J Cardiol 2010;106:865-72.
35. Rehman SU, Januzzi JL Jr. Natriuretic peptide testing in clinical medicine. Cardiol Rev 2008;16:240-9.